医学類学生の記事が掲載されます

医学類の学生を筆頭著者とする下記の総説が、Precision Medicine誌に掲載されます。スタッフの無茶ぶりに見事に応えて、M4のSさんが原稿を素早く仕上げてくれました。〇月前に原稿ができていたのですが、スタッフの対応が遅く申し訳ないです💦いつも(予想を上回る)迅速で丁寧な作業ありがとうございます。

Sanaka S, Sasaki T. From Monoclonal Antibodies to Small Molecules: The Evolution of IL-17A Inhibition for Neuropsychiatric Disorders. 2025-07. Precision Medicine.

Interleukin-17A (IL-17A) is a key cytokine mediating neuroinflammatory processes in mental and neurological disorders, including autism spectrum disorder (ASD). Existing monoclonal antibodies have limited blood-brain barrier permeability, making their application to mental disorders challenging. Currently, the development of low-molecular-weight IL-17A inhibitors is underway. In particular, thiazole-derived inhibitors developed using a scaffold-morphing strategy have demonstrated superior pharmacokinetic profiles while overcoming traditional safety concerns. This review discusses the technical advancements in low-molecular-weight IL-17A inhibitors and their potential for the treatment of mental disorders.